Children with early-onset atopic dermatitis (AD) have an elevated risk for pediatric uveitis, according to a study published ...

Keywords: Abrocitinib, atopic dermatitis (AD), JAK inhibitor (JAKi), ruxolitinib ... In that discussion, he noted that JAKi should warrant consideration as a first-line systemic therapy for AD.

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June ...

Phase 2b trials in atopic dermatitis and asthma are planned to ... robust STAT6 degradation in blood and skin by KT-621 has a dupilumab-like effect on reducing multiple Th2 biomarkers in the ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

In preclinical studies, KT-621 demonstrated dupilumab-like activity in several in vitro and in vivo models and ... More information on the KT-621 BroADen trial in AD will be available on ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...